Table 1 of Han, Mol Vis 2012; 18:1-9.

Table 1. Demography data of 24 patients with proliferative diabetic retinopathy.



No.
Gender
(F/M)
Age

(Y)		 Duration
of DR
(Mon)		 Duration
of diabetes
(Y)
Vision
(Snellen)
Vision
(LogMAR)

Laser

Medicine
Bevacizumab
injection
01 F 56 12 20 0.01 2.0 no insulin No
02 F 62 12 23 LP 2.7 Yes Insulin No
03 M 55 2 14 HM/30 cm 2.4 no hypoglycemic No
04 F 43 6 13 0.02 1.7 Yes Insulin Yes
05 F 40 6 10 HM/10 cm 2.4 no insulin Yes
06 M 49 6 15 HM/10 cm 2.4 no Insulin No
07 F 61 24 20 CF/15 cm 2.1 no hypoglycemic Yes
08 F 58 12 >1 0.02 1.7 Yes hypoglycemic Yes
09 M 54 24 16 HM/15 cm 2.4 Yes hypoglycemic No
10 M 42 1 1 0.06 1.2 Yes hypoglycemic Yes
11 F 46 24 >10 CF/10 cm 2.1 no insulin No
12 F 54 48 >15 HM/10 cm 2.4 no hypoglycemic No
13 M 50 14 15 HM/20 cm 2.4 no hypoglycemic Yes
14 F 61 21 16 CF/15 cm 2.1 no Insulin Yes
15 M 46 5 11 0.05 1.3 no hypoglycemic Yes
16 M 53 15 22 0.06 1.2 no Insulin No
17 F 44 24 19 CF/10 cm 2.1 no Insulin Yes
18 F 47 18 20 HM/15 cm 2.4 no Insulin No
19 M 56 9 10 0.05 1.3 no hypoglycemic Yes
20 F 62 12 14 0.02 1.7 no hypoglycemic No
21 M 55 6 12 HM/10 cm 2.4 no hypoglycemic Yes
22 M 48 10 15 HM/20 cm 2.4 no Insulin Yes
23 F 51 24 20 LP 2.7 Yes Insulin No
24 M 50 >24 >17 0.03 1.5 Yes insulin No

Gender, age, duration of diabetic retinopathy, duration of diabetes, vision and treatment of all the patients that enrolled in the study. Vision, Best-corrected visual acuity; CF, counting fingers; HM, hand motion; LP, light perception; laser, one session of scant retinal photocoagulation with less 500 spots; hypoglycemic, oral hypoglycemic drugs for control of blood glucose level.

Han, Mol Vis 2012; 18:1-9. http://www.molvis.org/molvis/v18/a1

©2012 Molecular Vision http://www.molvis.org/molvis/

ISSN 1090-0535